Vanda Pharmaceuticals Inc. (VNDA): Results of Operations and Financial Condition
Vanda Pharmaceuticals Inc. (VNDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results • Fanapt ® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31% • Full-year 2026 total revenue guidance of $240-$290 million • Cash totaled $170.0 million as of
How this was made
The 30-second read
Why it matters
Traders can update VNDA’s near-term expectations using the new full-year revenue guidance range, cash runway statement through at least end of 2027, and the dated FDA PDUFA target for Quimilza (Dec 12, 2026).
Market read
Primary disclosure of guidance, cash runway, and a fixed FDA decision date can drive repricing ahead of late-2026 catalysts.
What to watch
The 8-K notes revenue timing shifts for HETLIOZ orders shipped late June but recognized in Q3, which can create quarter-to-quarter noise in reported product sales.
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results
Fanapt and PONVORY growth and the initial NEREUS launch were offset by lower HETLIOZ sales, a larger net loss, and a material cash decline during a period of elevated launch and pipeline spending.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total net product salesGAAP | $50.5 million in Q2 2026 | – | a 4% decrease |
| Fanapt net product salesGAAP | $36.0 million in Q2 2026 | – | up 23% year-over-year |
| HETLIOZ net product salesGAAP | $5.6 million in Q2 2026 | – | down 66% year-over-year |
| PONVORY net product salesGAAP | $7.9 million in Q2 2026 | – | up 12% year-over-year |
| NEREUS net product salesGAAP | $1.0 million in Q2 2026 | – | – |
| Loss before income taxesGAAP | $62.4 million in Q2 2026 | – | – |
| Net lossGAAP | $62.5 million in Q2 2026 | – | – |
| Diluted loss per shareGAAP | $1.04 in Q2 2026 | – | – |
| Total net product salesGAAP | $102.2 million in the first six months of 2026 | – | – |
| Fanapt net product salesGAAP | $65.5 million in the first six months of 2026 | – | up 24% year-over-year |
| HETLIOZ net product salesGAAP | $21.5 million in the first six months of 2026 | – | down 42% year-over-year |
| PONVORY net product salesGAAP | $14.1 million in the first six months of 2026 | – | up 11% year-over-year |
| NEREUS net product salesGAAP | $1.0 million in the first six months of 2026 | – | – |
| Loss before income taxesGAAP | $110.8 million in the first six months of 2026 | – | – |
| Net lossGAAP | $111.1 million in the first six months of 2026 | – | – |
| Diluted loss per shareGAAP | $1.86 in the first six months of 2026 | – | – |
| Fanapt total prescriptions (TRx)other | up 31% versus Q2 2025 | – | up 31% versus Q2 2025 |
| Fanapt new-to-brand prescriptions (NBRx)other | up 32% versus Q2 2025 | – | up 32% versus Q2 2025 |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| FanaptTotal prescriptions (TRx) were up 31% and new-to-brand prescriptions (NBRx) were up 32% versus Q2 2025. | $36.0 million in Q2 2026 | – | up 23% year-over-year |
| HETLIOZNet product sales do not include orders totaling approximately $7.0 million in revenue that were shipped on June 29, 2026 and arrived on July 1, 2026; these orders will be recognized as revenue in Q3 2026. | $5.6 million in Q2 2026 | – | down 66% year-over-year |
| PONVORYVanda continued execution on the commercialization of PONVORY. | $7.9 million in Q2 2026 | – | up 12% year-over-year |
| NEREUSNEREUS launched commercially in the U.S. in Q2 2026 with a direct-to-consumer offering via the web portal nereus.us; personal promotion is expected to commence later in 2026. | $1.0 million in Q2 2026 | – | – |
Full Year 2026 outlook
- Revenue$240 to $290 million
- NoteFanapt and BYSANTI net product sales: $150 to $170 million
- NoteNEREUS net product sales: $10 to $30 million
- NoteOther net product sales: $80 to $90 million
- NoteVanda expects operating expenses to begin decreasing by the end of 2026 and more substantially throughout 2027.
- NoteVanda expects to have sufficient resources to fund operations through at least the end of 2027.
What drove it
- Fanapt net product sales increased 23% year-over-year, while TRx increased 31% and NBRx increased 32% versus Q2 2025.
- PONVORY net product sales increased 12% year-over-year.
- NEREUS became commercially available in Q2 2026 and generated $1.0 million in net product sales.
- BYSANTI received FDA approval in Q1 2026 and is expected to launch in the second half of 2026.
- The Quimilza BLA for GPP is under FDA review, with a PDUFA target action date of December 12, 2026.
Concerns
- HETLIOZ net product sales declined 66% year-over-year to $5.6 million in Q2 2026.
- Total net product sales declined 4% year-over-year to $50.5 million in Q2 2026.
- Net loss was $62.5 million in Q2 2026, compared with a net loss of $27.2 million in Q2 2025.
- Cash decreased by $32.3 million in Q2 2026 and by $93.8 million compared to December 31, 2025.
- Vanda cited significantly increased operating expenses in 2025 and 2026 from Phase III programs, commercialization, launch preparations, and commercial-supply manufacturing.
What to watch
- Commercial launch of BYSANTI in the second half of 2026.
- Personal promotion for NEREUS, expected to commence later in 2026.
- The Quimilza PDUFA target action date of December 12, 2026.
- Thetis Phase III results for NEREUS in patients receiving GLP-1 receptor agonist therapies, expected in 2026.
- Phase III results for VQW-765 in social anxiety disorder and HETLIOZ in delayed sleep phase disorder, expected in 2026.
- Whether operating expenses begin decreasing by the end of 2026.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities totaled $170.0 million as of June 30, 2026.
- Cash decreased by $32.3 million in Q2 2026.
- Cash decreased by $93.8 million compared to December 31, 2025.
- Vanda expects its current cash position and anticipated revenues to fund operations through at least the end of 2027.
Analysis
Vanda reported total net product sales of $50.5 million in Q2 2026, a 4% decrease from $52.6 million in Q2 2025. Fanapt was the principal source of commercial growth, with net product sales of $36.0 million, up 23% year-over-year, supported by TRx growth of 31% and NBRx growth of 32%. PONVORY added growth, with net product sales of $7.9 million, up 12% year-over-year. NEREUS generated $1.0 million following its U.S. commercial launch in Q2 2026.
HETLIOZ remained the key drag on reported sales. Its Q2 net product sales were $5.6 million, down 66% year-over-year. Management stated that this amount excludes approximately $7.0 million of revenue from orders shipped on June 29, 2026 that arrived on July 1, 2026, which will be recognized in Q3 2026. For the first six months, total net product sales were $102.2 million compared with $102.6 million in the first six months of 2025, while Fanapt sales rose 24% and HETLIOZ sales declined 42%.
Losses and cash usage increased as Vanda advanced Phase III programs, prepared product launches, and manufactured commercial supply. Loss before income taxes was $62.4 million in Q2 2026 versus $34.9 million in Q2 2025, and GAAP net loss was $62.5 million versus $27.2 million. Cash, cash equivalents and marketable securities totaled $170.0 million as of June 30, 2026, after a $32.3 million decrease in Q2 2026 and a $93.8 million decrease compared to December 31, 2025. Management expects expenses to begin decreasing by the end of 2026 and more substantially throughout 2027.
The company reiterated full-year 2026 total revenue guidance of $240 to $290 million. The commercial outlook depends on Fanapt, the expected second-half 2026 BYSANTI launch, and NEREUS expansion, for which personal promotion is expected later in 2026. The near-term regulatory and development calendar includes the December 12, 2026 PDUFA target action date for Quimilza and expected 2026 Phase III results for NEREUS in GLP-1-related vomiting, VQW-765 in social anxiety disorder, and HETLIOZ in delayed sleep phase disorder.
Management, verbatim
We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to patients. With BYSANTI approved and on track for launch in the second half of 2026, a December 2026 PDUFA date for Quimilza and multiple late-stage clinical trial results expected before year-end, we believe Vanda is well positioned for meaningful commercial expansion and pipeline value creation.
Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board
As our Phase III programs, launch preparations, and commercial supply manufacturing near completion, we expect operating expenses to begin moderating later this year and more significantly in 2027. Our current resources, together with anticipated product revenues, provide a solid foundation to advance our objectives through at least the end of 2027.
Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of the Board
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating income or loss
- Operating expenses by line item
- Income tax expense or benefit and tax rate
- Non-GAAP financial measures, including non-GAAP EPS
- Prior-quarter comparisons for sales, losses, EPS, and prescription trends
- Cash flow from operations
- Free cash flow
- Debt balance
- Share repurchases
- Dividends
- Prior outlook section needed to compare reported results with prior guidance
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Vanda’s SEC Form 8-K (Item 2.02) reporting Q2 2026 financial and operational results, plus regulatory and late-stage clinical milestones.
Ticker impact
Vanda reported Q2 2026 results, including Fanapt sales up 23% and full-year 2026 revenue guidance of $240-$290 million.
Near-term bias higher on guidance and FDA milestone visibility, with volatility around the Dec 12, 2026 PDUFA for Quimilza.
The filing is a primary disclosure with specific guidance ($240-$290M), cash balance ($170.0M as of June 30, 2026), and a dated FDA action target (Dec 12, 2026) plus an FDA approval (BYSANTI) and commercial launch updates (NEREUS).
Market effects
Adds incremental datapoints on commercial traction in CNS and antiemetic/rare-disease launches, relevant to small-cap pharma sentiment.
Japan orphan designation for Quimilza is a supportive international regulatory signal, though not a US catalyst by itself.
FDA review progress and a fixed PDUFA date can influence broader biotech risk appetite for similar-stage programs.
Counterpoint
Fanapt growth is offset by steep declines in HETLIOZ, and the company’s cash decreased sharply in Q2, so the runway depends on execution and launch timing.
Key entities
- companyVanda Pharmaceuticals Inc.
Nasdaq-listed biopharma reporting Q2 2026 results, revenue guidance, cash position, and pipeline/regulatory milestones.
- productFanapt (iloperidone)
Q2 2026 net product sales rose 23% to $36.0 million, with prescription growth highlighted.
- productBYSANTI (milsaperidone)
FDA approved in Q1 2026 for bipolar I disorder and schizophrenia; launch expected in second half of 2026.
- productQuimilza (imsidolimab)
BLA for GPP under FDA review with a PDUFA target action date of Dec 12, 2026.
- productNEREUS (tradipitant)
Commercially available in Q2 2026; Q2 net product sales were $1.0 million and launch via web portal began in Q2.
